When was $PEPG first mentioned on Surfaced?

The earliest tracked mention of $PEPG in the Surfaced archive was on Mar 4, 2026.

How many voices track $PEPG?

2 FinTwit voices have mentioned $PEPG 7 times in the past 12 months.

What kind of voices mention $PEPG most?

$PEPG is mentioned most by Long Research voices on Surfaced.

Last 12mo stats

mentions

voices

$PEPG

Q: Who mentions $PEPG most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $PEPG most — 4 mentions in the past 12 months.

PepGen Inc

$PEPG

PepGen Inc

Past 12mo:7mentions2voices

All voices7 mentions since Mar 2026calls only

Loading price chart…

About this stock

$PEPG has generated 7 mentions from 2 distinct FinTwit voices over the past 12 months, with discussion beginning on March 4, 2026. @investmentguru_ leads engagement with 4 mentions, followed by @adamfeuerstein with 3 mentions. The most recent activity occurred on March 30, 2026, centered around mixed trial data that moved the stock to $2.38 in after-hours trading. Both voices engage in long research-oriented discussion of the company.

AI-generated from tracked posts · updated Sep 5, 2026

Frequently asked

Who mentions $PEPG most on Surfaced?

Related stocks

$ALKSAlkermes

$ALMSAlumis

$ASNDAscendis Pharma A/S

$ATAIATAI Life Sciences

Recent mentions

7 mentions

@investmentguru_Mar 30, 2026 · 10:46 PM

$PEPG at $2.38 AH ON MIXED TRIAL DATA.

Open on X

@adamfeuersteinMar 30, 2026 · 8:55 PM

Oh no, I shouldn't make fun of $PEPG, not even tangentially. I didn't know it was another RA Capital holding. I might be subjected to a second tweetstorm from @PeterKolchinsky about "waste." 😉

Open on X

@adamfeuersteinMar 30, 2026 · 8:29 PM

$PEPG Live by the tiny N, die by the tiny N. I look forward to the day, coming soon, when some dipshit biotech will exclude all the patients from their analysis, and just declare victory.

Open on X

@investmentguru_Mar 16, 2026 · 5:17 PM

$PEPG

Open on X

@investmentguru_Mar 15, 2026 · 12:42 PM

$PEPG could become a major platform in genetic medicine One of the biggest challenges in gene therapy and RNA medicine is simple: Getting drugs inside the right cells. PepGen is building a platform that may solve that problem. Core Technology: EDO Platform PepGen developed EDO (Enhanced Delivery Oligonucleotide) technology. It uses engineered peptides to deliver RNA therapies into cells. Think of it like: a molecular delivery vehicle for gene therapy drugs. Why Delivery Matters RNA drugs often struggle to reach: • muscle tissue • nerve cells • brain tissue PepGen’s peptide technology may dramatically increase delivery efficiency. This could unlock therapies for diseases that are currently hard to treat. Lead Program PGN-EDO51 Target disease: Duchenne Muscular Dystrophy (DMD) DMD is a rare genetic disorder that causes progressive muscle degeneration. The therapy aims to restore production of dystrophin, a key muscle protein. Platform Potential If the EDO platform works, it could expand into treatments for: • neuromuscular diseases • rare genetic disorders • neurological conditions This makes PepGen potentially a platform company rather than a single-drug company. Key Catalysts • clinical data from the CONNECT trials • new disease indications • potential partnerships with large pharma Risks Early-stage biotech risks include: • clinical trial failures • regulatory challenges • capital raises causing dilution Cash in hand • $150 million Investment Perspective If PepGen proves its delivery technology works, it could become an essential partner for RNA and gene therapy companies. That’s why many biotech investors are keeping $PEPG on their radar. Not a financial advice

Open on X

@investmentguru_Mar 15, 2026 · 12:22 PM

6 Peptide Biotech Stocks to watch for future. $BCYC •Tumor-targeting bicyclic peptides •Oncology + peptide-drug conjugates •Could attract major pharma buyouts if trials succeed $ENTX •Oral peptide delivery—no injections needed •Osteoporosis & metabolic disease drugs •Potential to disrupt $100B injectable peptide market $LSTA •Peptides that help chemotherapy drugs penetrate tumors •Oncology-focused with Phase 2/3 catalysts $CUE •Peptide-MHC molecules activate immune cells •Precision immunotherapy for cancer & autoimmune diseases $VTGN •Neuropeptide nasal sprays •Rapid-acting treatments for social anxiety disorder •Huge potential psychiatric market if trials succeed $PEPG •Peptide-enhanced delivery of RNA therapies •Focus on rare genetic diseases, e.g., Duchenne muscular dystrophy •Solves one of biotech’s biggest challenges: getting therapies inside cells efficiently •Could become a major platform play if delivery technology proves successful The peptide revolution is already underway: •GLP-1 drugs proved the market is massive •AI-designed peptides accelerate drug discovery •Small-cap peptide biotech companies often become multi-bagger winners after clinical successes High risk, high reward — clinical-stage biotechs are volatile. But the next biotech cycle could be defined by peptides.

Open on X

@adamfeuersteinMar 4, 2026 · 9:14 PM

$PEPG FDA partial clinical hold on DM1 trial

Open on X